Cargando…

Neutralizing antiviral antibody responses

Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinkernagel, Rolf M., Lamarre, Alain, Ciurea, Adrian, Hunziker, Lukas, Ochsenbein, Adrian F., Mccoy, Kathy D., Fehr, Thomas, Bachmann, Martin F., Kalinke, Ulrich, Hengartner, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130890/
https://www.ncbi.nlm.nih.gov/pubmed/11680006
http://dx.doi.org/10.1016/S0065-2776(01)79001-3
_version_ 1783517113506332672
author Zinkernagel, Rolf M.
Lamarre, Alain
Ciurea, Adrian
Hunziker, Lukas
Ochsenbein, Adrian F.
Mccoy, Kathy D.
Fehr, Thomas
Bachmann, Martin F.
Kalinke, Ulrich
Hengartner, Hans
author_facet Zinkernagel, Rolf M.
Lamarre, Alain
Ciurea, Adrian
Hunziker, Lukas
Ochsenbein, Adrian F.
Mccoy, Kathy D.
Fehr, Thomas
Bachmann, Martin F.
Kalinke, Ulrich
Hengartner, Hans
author_sort Zinkernagel, Rolf M.
collection PubMed
description Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distinguish between virus serotypes; (2) B cell reactivity is determined by antigen structure, concentration, and time of availability in secondary lymphoid organs; and (3) B cell memory is provided by elevated protective antibody titers in serum that are depending on antigen stimulation. These perhaps slightly overstated rules are simple, correlate with in vivo evidence as well as clinical observations, and appear to largely demystify many speculations about antibodies and B cell physiology. The chapter also considers successful vaccines and compares them with those infectious diseases where efficient protective vaccines are lacking, it is striking to note that all successful vaccines induce high levels of neutralizing antibodies (nAbs) that are both necessary and sufficient to protect the host from disease. Successful vaccination against infectious diseases such as tuberculosis, leprosy, or HIV would require induction of additional long-lasting T cell responses to control infection.
format Online
Article
Text
id pubmed-7130890
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71308902020-04-08 Neutralizing antiviral antibody responses Zinkernagel, Rolf M. Lamarre, Alain Ciurea, Adrian Hunziker, Lukas Ochsenbein, Adrian F. Mccoy, Kathy D. Fehr, Thomas Bachmann, Martin F. Kalinke, Ulrich Hengartner, Hans Adv Immunol Article Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distinguish between virus serotypes; (2) B cell reactivity is determined by antigen structure, concentration, and time of availability in secondary lymphoid organs; and (3) B cell memory is provided by elevated protective antibody titers in serum that are depending on antigen stimulation. These perhaps slightly overstated rules are simple, correlate with in vivo evidence as well as clinical observations, and appear to largely demystify many speculations about antibodies and B cell physiology. The chapter also considers successful vaccines and compares them with those infectious diseases where efficient protective vaccines are lacking, it is striking to note that all successful vaccines induce high levels of neutralizing antibodies (nAbs) that are both necessary and sufficient to protect the host from disease. Successful vaccination against infectious diseases such as tuberculosis, leprosy, or HIV would require induction of additional long-lasting T cell responses to control infection. Published by Elsevier Inc. 2001 2004-01-07 /pmc/articles/PMC7130890/ /pubmed/11680006 http://dx.doi.org/10.1016/S0065-2776(01)79001-3 Text en Copyright © 2001 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zinkernagel, Rolf M.
Lamarre, Alain
Ciurea, Adrian
Hunziker, Lukas
Ochsenbein, Adrian F.
Mccoy, Kathy D.
Fehr, Thomas
Bachmann, Martin F.
Kalinke, Ulrich
Hengartner, Hans
Neutralizing antiviral antibody responses
title Neutralizing antiviral antibody responses
title_full Neutralizing antiviral antibody responses
title_fullStr Neutralizing antiviral antibody responses
title_full_unstemmed Neutralizing antiviral antibody responses
title_short Neutralizing antiviral antibody responses
title_sort neutralizing antiviral antibody responses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130890/
https://www.ncbi.nlm.nih.gov/pubmed/11680006
http://dx.doi.org/10.1016/S0065-2776(01)79001-3
work_keys_str_mv AT zinkernagelrolfm neutralizingantiviralantibodyresponses
AT lamarrealain neutralizingantiviralantibodyresponses
AT ciureaadrian neutralizingantiviralantibodyresponses
AT hunzikerlukas neutralizingantiviralantibodyresponses
AT ochsenbeinadrianf neutralizingantiviralantibodyresponses
AT mccoykathyd neutralizingantiviralantibodyresponses
AT fehrthomas neutralizingantiviralantibodyresponses
AT bachmannmartinf neutralizingantiviralantibodyresponses
AT kalinkeulrich neutralizingantiviralantibodyresponses
AT hengartnerhans neutralizingantiviralantibodyresponses